socalTECH
AUGUST 23, 2013
Financial details of the acquisition were not announced. According to XIFIN, it acquired the product and service assets and related intellectual property of PathCentral in the deal. PathCentral had been venture backed by Arboretum Ventures, Baird Venture Partners, and Okapi Venture Capital. READ MORE>>.
socalTECH
JUNE 30, 2010
TargeGen's products are also potentially useful in treating certain forms of leukemia, lymphoma, other hematological malignancies and blood disorders. Tags: targegen sanofi aventis merger acquisition lifescience bioscience. According to TargeGen, the deal's purchase price depends on the achievement of certain future milestones events.
Expert insights. Personalized for you.
138 
Let's personalize your content